Synergistic effect of resveratrol and radiotherapy in control of cancers

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6197-6208

  Kma, Lakhan ^a  

^a NORTH EASTERN HILL UNIVERSITY   (India)

Author keywords

Apoptosis; Radiosensitivity; Radiotherapy; Resveratrol; Tumour

Indexed keywords

RADIOSENSITIZING AGENT; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; APOPTOSIS; CELL PROLIFERATION; CHEMORADIOTHERAPY; DRUG EFFECTS; HUMAN; NEOPLASMS; RADIATION DOSE; RADIATION RESPONSE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CHEMORADIOTHERAPY; HUMANS; NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; STILBENES;

EID: 84892463102     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6197     Document Type: Review

References (67)

1. Aravindan S, Natarajan M, Herman TS, et al (2013). Molecular basis of 'hypoxic' breast cancer cell radio-sensitization: phytochemicals converge on radiation induced Rel signaling. Radiat Oncol, 8, 46-7.
2. Baatout S, Derradji H, Jacquet P, et al (2005). Increased radiation sensitivity of an eosinophilic cell line following treatment with epigallocatechin-gallate, resveratrol and curcuma. Int J Mol Med, 15, 337-52.
3. Bao S, Wu Q, McLendon RE, et al (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-0.
4. Bastianetto S, Quirion R (2010). Heme oxygenase 1: another possible target to explain the neuroprotective action of resveratrol, a multifaceted nutrient-based molecule. Exp Neurol, 225, 237-9.
5. Baur JA, Sinclair DA (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov, 5, 493-06.
6. Benitez DA, Hermoso MA, Pozo-Guisado E, et al (2009). Regulation of cell survival by resveratrol involves inhibition of NF kappa B-regulated gene expression in prostate cancer cells. Prostate, 69, 1045-4.
7. Bisht KS, Bradbury CM, Mattson D, et al (2003). Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res, 63, 8984-95.
8. Brown JM (1999). The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res, 59, 5863-0.
9. Busquets S, Ametller E, Fuster G, et al (2007). Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett, 245, 144-8.
10. Camphausen K, Tofilon PJ (2004). Combining radiation and molecular targeting in cancer therapy. Cancer Biol Ther, 3, 247-0.
11. Carsten RE, Bachand AM, Bailey SM, et al (2008). Resveratrol reduces radiation-induced chromosome aberration frequencies in mouse bone marrow cells. Radiat Res, 169, 633-8.
12. Chiou SH, Kao CL, Chen YW, et al (2008a). Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS ONE, 3, 2090.
13. Collins R, Darby S, Davies C, et al (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of randomized trials. Lancet, 366, 2087-106.
14. Creagh, EM, Martin SJ (2001). Caspases: cellular demolition experts. Biochem Soc Trans, 29, 696-2.
15. Crook JM, Perry GA, Robertson S, et al (1995). Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology, 45, 624-1.
16. de la Lastra CA, Villegas I (2007). Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans, 35, 1156-0.
17. Debatin KM, Krammer PH (2004). Death receptors in chemotherapy and cancer. Oncogene, 23, 2950-66.
18. Delmas D, Jannin B, Latruffe N (2005). Resveratrol: preventing properties against vascular alterations and ageing. Mol Nutr Food Res, 49, 377-95.
19. Dennis M, Spiegler BJ, Hetherington CR, et al (1996). Neuropsychological sequelae of the treatment of children with medulloblastoma. J Neurooncol, 29, 91-1.
20. Di Franco R, Calvanese M, Murino P, et al (2012). Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor®). Radiat Oncol, 7, 12-8.
21. Elmore E, Lao XY, Kapadia R, et al (2006). The effect of dose rate on radiation-induced neoplastic transformation in vitro by low doses of low-LET radiation. Radiat Res, 166, 832-8.
22. Fang Y, Bradley MJ, Cook KM, Herrick EJ, Nicholl MB (2013). A potential role for resveratrol as a radiation sensitizer for melanoma treatment. J Surg Res, 183, 645-3.
23. Fang Y, DeMarco VG, Nicholl MB (2012). Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Sci, 103, 1090-8.
24. Filomeni G, Graziani I, Rotilio G, et al (2007). Trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr, 2, 295-5.
25. Forman JD, Oppenheim T, Liu H, et al (1993). Frequency of residual neoplasm in the prostate following threedimensional conformal radiotherapy. Prostate, 23, 235-3.
26. Fremont L (2000). Biological effects of resveratrol. Life Sci, 66, 663-3.
27. Gao HS, Rong X, Peng D, et al (2011). Cross-talk of the related bioactivity mediators in serum after injection of soluble TNF-a receptor on silicosis model of rats. Toxicol Ind Health, 27, 607-16.
28. Gautam SC, Xu YX, Dumaguin M, et al (2000). Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. Bone Marrow Transplant, 25, 639-5.
29. Habrand JL, De Crevoisier R (2001). Radiation therapy in the management of childhood brain tumors. Childs Nerv Syst, 17, 121-33.
30. Hagan M, Wang L, Hanley JR, et al (2000). Ionizing radiationinduced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res, 153, 371-83.
31. Hoppe-Hirsch E, Brunet L, Laroussinie F, et al (1995). Intellectual outcome in children with malignant tumors of the posterior fossa: influence of the field of irradiation and quality of surgery. Childs Nerv Syst, 11, 340-5.
32. Ivanov VN, Zhou H, Hei TK (2007). Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res, 67, 5397-7.
33. Johnson GE, Ivanov VN, Hei TK (2008). Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis, 13, 790-02.
34. Kabakov AE, Kudryavtsev VA, Gabai VL (2010). Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med, 88, 241-7.
35. Kao CL, Huang PI, Tsai PH, et al (2009). Resveratrol-induced apoptosis and increased radiosensitivity in CD 133-positive cells derived from atypical teratoid/rhabdoid tumor. Int J Radiat Oncol Biol Phys, 74, 219-8.
36. Kelley MR (2012). DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications, Academic Press, New York, NY, USA.
37. Lee JC, Kinniry PA, Arguiri E, et al (2010). Dietary Curcumin increases antioxidant defenses in lung, ameliorates radiationinduced pulmonary fibrosis, and improves survival in mice. Radiat Res, 173, 590-01.
38. Leith JT (1994). In vitro radiation sensitivity of the LNCaP prostate tumor cell line. Prostate, 24, 119-4.
39. Leone S, Fiore M, Lauro MG, et al (2008). Resveratrol and X rays affect gap junction intercellular communications in human glioblastoma cells. Mol Carcinog, 47, 587-98.
40. Linard C, Marquette C, Mathieu J, et al (2004). Acute induction of inflammatory cytokine expression after gamma-irradiation in the rat: effect of an NF-kB inhibitor. Int J Radiat Oncol Biol Phys, 58, 427-4.
41. Lu KH, Chen YW, Tsai PH, et al (2009). Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells. Childs Nerv Syst, 25, 543-0.
42. Machida H, Matsumoto Y, Shirai M, et al (2003). Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol, 79, 9730.
43. Mcllwain DR, Berger T, Mak TW (2013). Caspase functions in cell death and disease. Cold Spring Harb Perspect Med, 3, 8656.
44. Moeller BJ, Dreher MR, Rabbani ZN, et al (2005). Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cells, 8, 99-10.
45. Moon SH, Shin KH, Kim TH, et al (2009). Dosimetric comparison of four different external beam partial breast irradiation techniques: three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, helical tomotherapy, and proton beam therapy. Radiother Oncol, 90, 66-3.
46. Nguyen HG, Ravid K (2006). Tetraploidy/aneuploidy and stem cells in cancer promotion: the role of chromosome passenger proteins. J Cell Physiol, 208, 12-2.
47. Oh YC, Kang OH, Choi JG, et al (2009). Anti-inflammatory effect of resveratrol by inhibition of IL-8 production in LPS-induced THP-1 cells. Am J Chin Med, 37, 1203-14.
48. Okada H, Mak TW (2004). Pathways of apoptotic and nonapoptotic death in tumour cells. Nat Rev Cancer, 4, 592-3.
49. Pervaiz S (2003). Resveratrol: from grapevines to mammalian biology. FASEB J, 17, 1975-5.
50. Pervaiz S (2004). Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol. Drug Resist Updat, 7, 333-44.
51. Presser LD, McRae S, Waris G (2013). Activation of TGF-b1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-b1 in hepatic stellate cell activation and invasion. PLoS ONE, 8, 56367.
52. Rashid A, Liu C, Sanli T, et al (2011). Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiat Oncol, 6, 144-55.
53. Reagan-Shaw S, Mukhtar H, Ahmad N (2008) Resveratrol imparts photoprotection of normal cells and enhances the efficacy of radiation therapy in cancer cells. Photochem Photobiol, 84, 415-1.
54. Ruan K, Song G, Ouyang G (2009). Role of hypoxia in the hallmarks of human cancer. J Cell Biochem, 107, 1053-2.
55. Scarlatti F, Sala G, Ricci C, et al (2007). Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett, 253, 124-0.
56. Sowa M, Arthurs BJ, Estes BJ, et al (2006). Effects of ionizing radiation on cellular structures, induced instability and carcinogenesis. EXS, 96, 293-1.
57. Suit H, Goldberg S, Niemierko A, et al (2007). Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res, 167, 12-42.
58. Tak JK, Lee JH, Park JW (2012). Resveratrol and piperine enhance radiosensitivity of tumor cells. BMB Rep, 45, 242-6.
59. Ungvari Z, Labinskyy N, Mukhopadhyay P, et al (2009). Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol, 297, 1876-1.
60. Wang C, Chen L, Hou X, et al (2006). Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol, 8, 1025-1.
61. Wang H, Lathia JD, Wu Q, et al (2009). Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells, 27, 2393-04.
62. Weiss JF, Landauer MR (2003). Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology, 189, 1-20.
63. Xie Y, Zhang J, Xu Y, et al (2012). SirT1 confers hypoxiainduced radioresistance via the modulation of c-Myc stabilization on hepatoma cells. J Radiat Res, 53, 44-0.
64. Yang YP, Chang YL, Huang PI, et al (2012). Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol, 227, 976-93.
65. Yin HT, Tian QZ, Guan L, et al (2013). In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev, 14, 1703-6.
66. Zhou Y, Peng Y, Mao QQ, et al (2013). Casticin induces caspasemediated apoptosis via activation of mitochondrial pathway and upregulation of DR5 in human lung cancer cells. Asian Pac J Trop Med, 6, 372-8.
67. Zietman AL, Bae K, Slater JD, et al (2010). Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol, 28, 1106-1.